Regeneron Pharmaceuticals (NASDAQ:REGN) Sets New 52-Week High at $1,165.95

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s share price hit a new 52-week high on Thursday . The stock traded as high as $1,165.95 and last traded at $1,159.10, with a volume of 34372 shares trading hands. The stock had previously closed at $1,156.86.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on REGN shares. Barclays increased their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Morgan Stanley reduced their price target on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. Cantor Fitzgerald raised their price target on shares of Regeneron Pharmaceuticals from $925.00 to $1,000.00 and gave the company a “neutral” rating in a report on Monday, July 22nd. Argus upped their price objective on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a report on Tuesday, June 25th. Finally, JPMorgan Chase & Co. increased their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. One research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $1,097.05.

Regeneron Pharmaceuticals Trading Up 1.5 %

The company has a market capitalization of $129.36 billion, a P/E ratio of 34.18, a PEG ratio of 2.99 and a beta of 0.13. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. The business’s 50-day moving average price is $1,063.88 and its two-hundred day moving average price is $992.29.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The firm had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. During the same period in the previous year, the company posted $8.79 earnings per share. The company’s revenue for the quarter was up 12.3% on a year-over-year basis. As a group, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current fiscal year.

Insider Buying and Selling

In other news, VP Jason Pitofsky sold 487 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the transaction, the vice president now owns 4,204 shares in the company, valued at $4,498,280. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the sale, the vice president now directly owns 4,204 shares of the company’s stock, valued at approximately $4,498,280. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Joseph J. Larosa sold 1,866 shares of the stock in a transaction dated Thursday, July 11th. The stock was sold at an average price of $1,088.95, for a total value of $2,031,980.70. Following the transaction, the executive vice president now owns 37,937 shares of the company’s stock, valued at approximately $41,311,496.15. The disclosure for this sale can be found here. In the last three months, insiders sold 40,561 shares of company stock valued at $40,585,963. 7.48% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Large investors have recently bought and sold shares of the company. SVB Wealth LLC increased its stake in Regeneron Pharmaceuticals by 40.0% in the 4th quarter. SVB Wealth LLC now owns 1,117 shares of the biopharmaceutical company’s stock valued at $981,000 after buying an additional 319 shares during the last quarter. Slow Capital Inc. increased its position in shares of Regeneron Pharmaceuticals by 0.4% in the fourth quarter. Slow Capital Inc. now owns 11,844 shares of the biopharmaceutical company’s stock valued at $10,402,000 after acquiring an additional 47 shares during the last quarter. Daiwa Securities Group Inc. raised its holdings in Regeneron Pharmaceuticals by 3.5% during the fourth quarter. Daiwa Securities Group Inc. now owns 15,086 shares of the biopharmaceutical company’s stock worth $13,250,000 after acquiring an additional 514 shares in the last quarter. Livforsakringsbolaget Skandia Omsesidigt boosted its position in Regeneron Pharmaceuticals by 1.4% during the fourth quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 8,632 shares of the biopharmaceutical company’s stock valued at $7,577,000 after purchasing an additional 118 shares during the last quarter. Finally, Federated Hermes Inc. grew its stake in Regeneron Pharmaceuticals by 14.9% in the fourth quarter. Federated Hermes Inc. now owns 3,214 shares of the biopharmaceutical company’s stock valued at $2,823,000 after purchasing an additional 418 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.